Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01354431 · ClinicalTrials.gov registry record · Phase 2
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
NCT01354431 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 168 participants.
The verdict
NCT01354431, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
Study Summary
The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.
Interventions
- BIOLOGICAL nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2011-05-31 |
| Est. Completion | 2021-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01354431
The ClinicalTrials.gov registry entry for NCT01354431 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nivolumab is the first listed.
NCT01354431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01354431 about?
NCT01354431 is a clinical study titled "BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)". The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.
What is the current status of trial NCT01354431?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2011-05-31. Estimated completion is 2021-04-15.
What interventions are being tested in trial NCT01354431?
The interventions under investigation include: nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01354431?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.